Ovarian Cancer-Targeted Exosome Modification Service
- Choose the appropriate exosome source based on client goals;
- Customize targeting modification strategies (ligand type, drug loading type).
- Use ultracentrifugation + size exclusion chromatography (SEC) or polymer precipitation to ensure high purity and activity of exosomes;
- Verify exosomal markers (CD63/TSG101) using NTA and Western Blot.
- Membrane modification: Add targeting ligands using chemical conjugation or genetic engineering techniques;
- Drug loading: Choose active drug loading (electroporation) or passive encapsulation techniques based on requirements.
- In vitro validation: Co-culture experiments to evaluate targeting efficiency (flow cytometry, confocal microscopy);
- In vivo validation: Evaluate tumor accumulation efficiency and efficacy in ovarian cancer mouse models;
- Systemic characterization: Stability, drug loading capacity, release kinetics analysis.
- Complete experimental process records;
- Test results (electron microscope images, targeting efficiency, efficacy data);
- Personalized optimization recommendations.
- Our proprietary ligand library matches molecular features of different ovarian cancer subtypes;
- Transmembrane penetration technology enhances exosome ability to penetrate complex tumor microenvironments.
- Strict monitoring of exosome yield, purity, and bioactivity to avoid batch-to-batch variation;
- Standardized operating procedures following GLP standards to ensure data reproducibility.
- Supports modifications from single-point (e.g., drug loading only) to complex functional designs;
- Develop combination treatment strategies targeting drug-resistant ovarian cancer models.
- Collaboration between experts in molecular biology, nanomedicine, and tumor pharmacology;
- One-stop service from mechanism exploration to animal experiments.
Exosomes are nanoscale (30-200 nm) lipid bilayer vesicles secreted by cells, widely present in body fluids such as blood and ascites. As "molecular couriers" for intercellular communication, exosomes naturally carry bioactive molecules like proteins and nucleic acids (such as miRNA and mRNA), with high biocompatibility, low immunogenicity, and excellent tissue penetration ability. In drug delivery, exosomes can be engineered to load therapeutic agents (e.g., siRNA, chemotherapy drugs) and target specific tissues or cells using surface proteins, enabling precise drug delivery, significantly enhancing efficacy while reducing systemic toxicity.
The high mortality, metastasis, and drug resistance of ovarian cancer are primarily due to its hidden nature, tumor heterogeneity, and chemotherapy resistance. Early lesions are difficult to detect, and by the time of diagnosis, metastasis often has occurred. Furthermore, tumor heterogeneity makes it challenging for traditional drugs to differentiate between cancerous cells and normal tissue, affecting treatment effectiveness. Additionally, the tumor microenvironment, such as immune suppression and exudation barriers, significantly hinders drug penetration, leading to poor chemotherapy outcomes. Targeted therapy based on exosomes can overcome these challenges through the following modification strategies:
1. Targeting molecule conjugation: Introduce specific ligands (e.g., folate, RGD peptides, anti-EpCAM antibodies) on the exosome membrane to actively recognize overexpressed receptors on ovarian cancer cells for precise targeting;
2. Efficient drug loading: Load chemotherapy drugs (e.g., paclitaxel), gene therapy materials (e.g., siRNA, CRISPR), or immune regulators into exosomes through electroporation, chemical transfection, or genetic editing techniques;
3. Functional modifications: Knockout exosomal pro-cancer proteins (e.g., PD-L1) or enhance their permeability (e.g., integrin penetration peptides) to further improve delivery efficiency.
Bhavsar, D. et al. J Ovarian Res. 2024.
Figure 1. Exosomes as Nanocarriers Offers Several Benefits and Numerous Exosomes-Based Therapeutics Applied for Treating Ovarian Cancer
MtoZ Biolabs focuses on providing Ovarian Cancer-Targeted Exosome Modification Service for research institutions and pharmaceutical companies, empowering them from basic research to preclinical development. Through multidimensional engineering modifications, we transform natural exosomes into "smart drug delivery systems," helping clients develop efficient, low-toxicity ovarian cancer-targeted therapies. Our services include but are not limited to:
1. Exosome Cultivation: Healthy donor/patient-derived exosome isolation and culture;
2. Targeting Modification Technologies: Ligand conjugation (chemical/genetic engineering), membrane protein modification;
3. Drug Loading Services: Chemotherapy drugs, nucleic acid drugs (siRNA, mRNA), immune regulators;
4. Functional Verification Packages: Including targeting efficiency testing, in vitro efficacy evaluation, animal model experiments (optional).
Analysis Workflow
1. Communication and Plan Design
2. Exosome Isolation and Purification
3. Targeting Modification and Drug Loading
4. Functional Verification
5. Data Delivery and Reports
Service Advantages
1. Precise Targeting and Efficient Delivery
2. Full-Process Quality Control System
3. Customized Solutions
4. Cross-Disciplinary Technical Team
Applications
1. Overcoming Chemotherapy Resistance: Deliver siRNA to silence resistance genes and reverse paclitaxel resistance;
2. Liquid Biopsy Biomarker Development: Establish early diagnostic models for ovarian cancer based on exosomal nucleic acid profiles;
3. Immune Microenvironment Remodeling: Deliver IL-12 or PD-1 inhibitors to activate anti-tumor immune responses;
4. Precise Treatment of Metastasis: Target peritoneal metastasis and deliver MMP inhibitors to suppress invasion and spread.
Case Study
1. Genetically Engineered Artificial ExosomeConstructed Hydrogel for Ovarian Cancer Therapy
This study reports a genetically engineered macrophage-derived artificial exosome-constructed hydrogel for treating advanced ovarian cancer with peritoneal metastasis. Utilizing Siglec-10-engineered M1-type macrophage-derived exosomes, combined with X-ray radiation-induced immunogenicity and the efferocytosis inhibitor MRX-2843, this hydrogel synergistically regulates polarization, phagocytosis, and antigen presentation by peritoneal macrophages, effectively eliminating tumor cells and enhancing immune responses. Additionally, this therapeutic strategy shows promising results for triple-negative breast cancer with high CD24 expression. Ovarian Cancer-Targeted Exosome Modification Service focuses on genetic engineering of exosomes to enhance their ovarian cancer-targeting specificity and therapeutic efficacy. By selectively modifying exosomal surface markers, it improves exosome accumulation in ovarian tumor sites and their modulation of the tumor microenvironment, facilitating targeted drug delivery and immune activation for precise cancer therapy.
Li, Q. et al. ACS Nano. 2023.
Figure 2. O-SM1Aexo@M Hydrogel Mediated Anti-Tumor Immunological Effect in a Mouse Advanced Ovarian Cancer Model
2. Exosomes in Ovarian Cancer Ascites Promote Epithelial–Mesenchymal Transition of Ovarian Cancer Cells by Delivery of miR-6780b-5p
This study investigates the role of ascites-derived exosomes (ADEs) in promoting ovarian cancer metastasis through the induction of epithelial-mesenchymal transition (EMT). The researchers identified miR-6780b-5p as a key microRNA within ADEs that facilitates EMT and enhances metastasis both in vitro and in vivo. The expression of miR-6780b-5p in exosomes was found to correlate with tumor metastasis in ovarian cancer patients. Overexpression of miR-6780b-5p promoted EMT, while its downregulation suppressed it, indicating that ADEs transfer this microRNA to cancer cells to promote metastasis. Ovarian Cancer-Targeted Exosome Modification Service focuses on engineering exosomes to optimize their targeting and therapeutic potential in ovarian cancer. By modifying exosomes to enhance their delivery of key molecules like miRNAs, it supports the modulation of cancer cell behaviors, potentially reducing metastasis and improving treatment outcomes.
Cai, J. et al. Cell Death Dis. 2021.
Figure 3. ADEs Transfer MiR-6780b-5p to Ovarian Cancer Cells
The future of ovarian cancer treatment lies in precision and personalization. MtoZ Biolabs' targeted exosome modification services combine the advantages of natural delivery carriers with cutting-edge engineering technologies, offering a new approach to overcoming ovarian cancer treatment bottlenecks. Whether you're in the early stages of drug development or in the preclinical translation phase, we provide cost-effective, flexible technical support to accelerate your research toward clinical applications. Contact MtoZ Biolabs today to start your new chapter in ovarian cancer targeted therapy!
How to order?
